Physician profile
John M Carter
NPI 1932425311
$3,425.30
in general payments reported to CMS, 2019-2025
12 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 89% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.37 · 2022: $166 · 2023: $340 · 2024: $1,213 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,837.66 | 2022-2025 | Propel, Stealthstation S8 Platform, Nim Vital |
| Grace Medical, INC. | $429.63 | 2025 | |
| Inspire Medical Systems, INC. | $328.23 | 2024-2025 | Inspire |
| Cochlear Americas | $196.74 | 2023-2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Aerin Medical INC. | $179.47 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $133.65 | 2023 | Dupixent |
| Acclarent, INC | $126.11 | 2024 | Acclarent Aera |
| Depuy Synthes Sales INC. | $60.37 | 2021 | |
| Daiichi Sankyo INC. | $50.03 | 2025 | Injectafer |
| Integra Lifesciences Corporation | $49.18 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Millicent US INC | $34.23 | 2024-2025 | Intrarosa, Femring |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.